There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Caremark is ending coverage of the popular weight-loss drug Zepbound effective July 1st, significantly impacting consumers. This shift is part of broader changes in the GLP-1 market, with ...

Zepbound users discuss weight loss after preliminary research touts effectiveness Eli Lilly highlighted its drug's effectiveness in helping people lose weight.

A targeted ozone injection technique guided by CT imaging effectively eased drug-resistant postherpetic neuralgia, reducing pain, hypersensitivity, and medication use over 1 year.

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, one method led to much more weight loss.

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound.

About Zepbound (tirzepatide) injection Zepbound is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication.

About Zepbound (tirzepatide) injection Zepbound is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication.